X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PTI-125 (simufilam) is a novel small molecule drug candidate that binds to altered filamin A protein in the brain and restores its normal shape and function. It is being evaluated for the treatment ofAlzheimer’s disease.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
PTI-125 (simufilam) is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. It binds to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
PTI-125 (simufilam) is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. It binds to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
PTI-125 (simufilam) is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. It binds to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
PTI-125 (simufilam) is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. It binds to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
PTI-125 (simufilam) is a novel drug candidate designed to treat and slow the progression of Alzheimer’s disease. It binds to an altered conformation of the filamin A protein (FLNA) that is present in the brain of the Alzheimer’s patient and is critical to the toxicity of Aβ42.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
PTI-125 (simufilam) is Cassava Sciences’ proprietary, small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain. Currently being developed for alzheimer’s disease.
Lead Product(s): Simufilam
Therapeutic Area: Oncology Product Name: PTI-125
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
PTI-125 (simufilam) is a small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain. Currently being investigated for alzheimer’s disease.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
PTI-125 (simufilam) is Cassava Sciences’ proprietary, small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain. Currently being developed for alzheimer’s disease.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
PTI-125 (simufilam) is a small molecule (oral) drug candidate that restores the normal shape and function of altered filamin a (flna) protein in the brain. it is currently being investigated as a potential treatment for alzheimer’s disease.
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
